Loading...
Please wait, while we are loading the content...
Similar Documents
Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
| Content Provider | Scilit |
|---|---|
| Author | Prince, H. Miles Martin, Ann G. Olsen, Elise A. Fivenson, David P. Duvic, Madeleine |
| Copyright Year | 2012 |
| Description | Journal: Leukemia & Lymphoma In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25 low expression). Patients received DD 18 μg/kg/day for 5 consecutive days every 3 weeks for up to eight courses. The primary endpoint, overall response rate, was 30.6% (95% confidence interval: 16.3, 48.1), 33.3% for stage IIA or lower disease, and 26.7% for stage IIB or greater disease. Median progression-free survival (PFS) was > 487 days, and median time to treatment failure was 68.5 days. No difference in PFS by disease stage was observed. The safety profile of DD in CD25 low-expression disease was similar to that in CD25+ disease. These findings suggest that CD25 low expression does not preclude a meaningful clinical response to DD in patients with CTCL. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523809/pdf |
| Ending Page | 75 |
| Page Count | 7 |
| Starting Page | 69 |
| ISSN | 10428194 |
| e-ISSN | 10292403 |
| DOI | 10.3109/10428194.2012.706286 |
| Journal | Leukemia & Lymphoma |
| Issue Number | 1 |
| Volume Number | 54 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2012-08-14 |
| Access Restriction | Open |
| Subject Keyword | Journal: Leukemia & Lymphoma Denileukin Diftitox Mycosis Fungoides Sézary Syndrome Cutaneous T-cell Lymphoma |
| Content Type | Text |
| Subject | Hematology Cancer Research Oncology |
